Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 in Combination With Other Drugs for Advanced Solid Tumour
NCT07390383Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of opamtistomig in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Leads Biolabs. Primary endpoint: Objective Response Rate. Started Apr 2026; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07390383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07390383.